Cereno Scientific to evaluate IPF drug as PH-ILD treatment
An innovative drug developed to treat idiopathic pulmonary fibrosis (IPF) will now be evaluated as a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
CS014, a HDAC inhibitor developed by biotech company Cereno Scientific, will be studied as a treatment for PH-ILD to address a patient population with high unmet clinical need.
Interstitial lung diseases (ILDs) are a group of fibrotic lung disorders, of which IPF is the most common. A substantial proportion of patients with ILD, including many with IPF, go on to develop pulmonary hypertension, a complication associated with significantly worse prognosis.
The rare disease PH-ILD is a severe and life-limiting condition associated with markedly worse outcomes compared with fibrotic lung disease alone, including IPF without pulmonary hypertension. ILD patients who develop pulmonary hypertension experience reduced exercise capacity, faster disease progression and high mortality.
Treatment options for PH-ILD remain very limited and largely focused on symptom management rather than disease modification.
“Broadening the development focus for CS014 to PH-ILD is a natural and scientifically driven evolution,” said Sten Sörensen, CEO of Cereno Scientific.
“It enables us to target a severe condition with very limited treatment options and is expected to strengthen the clinical and strategic positioning of CS014 without changing its underlying scientific rationale or long-term development focus.
“The underlying rationale for this strategic focus is that we believe it will enable us to get CS014 faster to market at lower cost and with a higher probability of success.”
“CS014 targets key pathophysiological processes that are shared across fibrotic lung disease and pulmonary vascular disease, including vascular remodelling, fibrosis, thrombosis and inflammation,” added Rahul Agrawal, CMO and Head of R&D at Cereno Scientific.
“By broadening the development focus to PH-ILD, we can design a Phase II study that better reflects real-world disease biology and for patients with worse prognosis.”
